Prolia 60mg Injection

The human body reacts differently to Prolia 60mg Injection. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Prolia 60mg Injection are mentioned below:

• Rash
• Sciatica
• Musculoskeletal (bone, muscle, or joint) pain
• Infection in the upper respiratory tract
• Hair loss
• Headache
• Nerve pain
• Constipation
• Eczema
• Urinary tract infection
• Hypercholesterolemia (high cholesterol)
• Cystitis
  
• Fatigue
• Hypocalcemia
  

• The Prolia 60mg injection is injected in your upper thigh, stomach, or upper arm. Normally, you get it every 6 months.
  
• For more information, talk to your doctor. This injection should not be self-administered and should be given by a health care professional.
  
• To make it more effective, take a balanced diet and take an adequate amount of Vitamin D and calcium while on treatment with Prolia 60mg injection.
  

• Green W. (2024). Denosumab (Prolia) Injection: A New Approach to the Treatment of Women With Postmenopausal Osteoporosis. P T, 35(10):553–9 - https://pmc.ncbi.nlm.nih.gov/articles/PMC2957751/
• Aubin JE, Bonnelye E. (2025). Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 11:905–913 - https://pubmed.ncbi.nlm.nih.gov/11193242/
• Sattler A, Schoppet M, et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int. 74:103–106 - https://pubmed.ncbi.nlm.nih.gov/14523602/
•  Nicolopoulos K, Moshi MR, Stringer D, Ma N, Jenal M, Vreugdenburg T. (2025). The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis. Arch Osteoporos. 10;18(1):18.
• Jamshidi, A., Vojdanian, M., Soroush, M. et al.  (2025). Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Res Ther 24, 161 - https://pubmed.ncbi.nlm.nih.gov/35773713/
• Francisco A. (2024). Sylvester, Effects of Digestive Diseases on Bone Metabolism. Pediatric Gastrointestinal and Liver Disease, (1116-1125.e8).
• Savelli,G.,Oliviero,S.,Viceconti,M.,Mattina,M,L,A., (2025). In silico prediction of hip fractures: improved fall modeling and expanded validation across cohorts with diverse risk profiles, Journal of the Mechanical Behavior of Biomedical Materials, 172, (107182) -https://pubmed.ncbi.nlm.nih.gov/40913997/
• Singh, Inderjeet; Jose, Vinu; Patel, Ronak; Arora, Sumit INTP23. (2025). Study 051-14 Investigator Team. Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial. Indian Journal of Pharmacology 53(1):p 6-12.